sorafenib has been researched along with brusatol in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (brusatol) | Trials (brusatol) | Recent Studies (post-2010) (brusatol) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 89 | 0 | 76 |
| Protein | Taxonomy | sorafenib (IC50) | brusatol (IC50) |
|---|---|---|---|
| Nuclear factor erythroid 2-related factor 2 | Homo sapiens (human) | 0.0292 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, PS; Ebinuma, H; Fukasawa, M; Ikeda, M; Kanai, T; Kato, N; Koda, Y; Murakami, Y; Nakamoto, N; Ojiro, K; Saito, H; Saito, K; Saito, Y; Sugiyama, K; Suzuki, T; Taniki, N; Teratani, T | 1 |
1 other study(ies) available for sorafenib and brusatol
| Article | Year |
|---|---|
Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells.
Topics: Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Hepatitis C; Humans; Liver Neoplasms; NF-E2-Related Factor 2; Quassins; RNA, Viral; Sorafenib; Transcriptome; Virus Replication | 2018 |